Detection of clonal immunologlobulin and T-cell receptor gene recombination in hematological malignancies: Monitoring minimal residual disease

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 2, 2009, Pages 124-135

  Barros Núñez, Patricio ^a   García Castillo, Herbert ^a,b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Clonal rearrangement; Hematological malignancy; Lymphoproliferative disease; Minimal residual disease; Monoclonality

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; IMMUNOGLOBULIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIBODY DETECTION; B LYMPHOCYTE; CANCER CELL; CANCER DIAGNOSIS; CANCER RISK; CELL LINEAGE; CLONAL VARIATION; CLONOGENIC ASSAY; GENE LOCUS; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC RECOMBINATION; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOCYTE DIFFERENTIATION; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; PATIENT MONITORING; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; BLOOD; BLOOD DISEASE; CELL CLONE; GENETICS; IMMUNOLOGY; METABOLISM; POLYMERASE CHAIN REACTION;

B-LYMPHOCYTES; CLONE CELLS; GENE REARRANGEMENT; GENES, T-CELL RECEPTOR; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOGLOBULINS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 68349108225     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152909788488627     Document Type: Review

References (90)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA. Cancer J. Clin., 2008, 58, 71-96.
2. Jaffe, E.S.; Harris, N.L.; Stein, H.; Vardiman, J.W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC press: Lyon, 2001.
3. van der Velden, V.H.; Hochhaus, A.; Cazzaniga, G.; Szczepanski, T.; Gabert J.; van Dongen, J.J. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia, 2003, 17, 1013-1034.
4. Langerak, A.W.; van Krieken, J.H.; Wolvers-Tettero, I.L.; Kerkhof, E.; Mulder, A.H.; Vrints, L.W.; Coebergh, J.W.; Schuuring, E.; Kluin, P.M.; van Dongen, J.J. The role of molecular analysis of immunoglobulin and T cell receptor gene rearrangements in the diagnosis of lymphoproliferative disorders. J. Clin. Pathol., 2001, 54, 565-567.
5. Sandberg, Y.; Verhaaf, B.; van Gastel-Mol, E.J.; Wolvers-Tettero, I.L.; de Vos, J.; Macleod, R.A.; Noordzij, J.G.; Dik, W.A.; van Dongen, J.J.; Langerak, A.W. Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes. Leukemia, 2007, 21, 230-237.
6. Montes, C.L.; Acosta-Rodríguez, E.V.; Merino, M.C.; Bermejo, D.A.; Gruppi, A. Polyclonal B cell activation in infections: infectious agents' devilry or defense mechanism of the host? J. Leukoc. Biol., 2007, 82, 1027-1032.
7. Rodríguez-Rojas, L.X.; Leal-Ugarte, E.; Medina-Lozano, C.; Jaloma-Cruz, A.R.; Rangel, H.; Martín, F.; Barros-Núñez, P. Monoclonal detection in enlarged lymph nodes for B-cell lymphoma diagnosis: Comparasion with the clinical course of patients. Recent Adv. Res. Updates, 2006, 7, 41-46.
8. Langerak, A.W.; Molina, T.J.; Lavender, F.L.; Pearson, D.; Flohr, T.; Sambade, C.; Schuuring, E.; Al Saati, T.; van Dongen, J.J.; van Krieken, J.H. Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 2007, 21, 222-229.
9. van Dongen, J.J.; Langerak, A.W.; Bruggemann, M.; Evans, P.A.; Hummel, M.; Lavender, F.L.; Delabesse, E.; Davi, F.; Schuuring, E.; Garcia-Sanz, R.; van Krieken, J.H.; Droese, J.; González, D.; Bastard, C.; White, H.E.; Spaargaren, M.; González, M.; Parreira, A.; Smith, J.L.; Morgan, G.J.; Kneba, M.; Macintyre, E.A. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 2003, 17, 2257-2317.
10. Leal, E.; Esparza-Flores, M.A.; López-Guido, B.; Aguilar-Luna, C.; Aguilar-López, L.; Jaloma- Cruz, A.R.; Medina, C.; Barros-Núñez, P. Detection and monitoring of clonality in peripheral blood and bone marrow of patients with B-cell lymphoproliferative disorders. Hematol. Oncol., 2003, 21, 25-31.
11. Rawstron, A.C.; Owen, R.G.; Davies, F.E.; Johnson, R.J.; Jones, R.A.; Richards, S.J.; Evans, P.A.; Child, J.A.; Smith, G.M.; Jack, A.S.; Morgan, G.J. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br. J. Haematol., 1997, 97, 46-55.
12. Owen, R.G.; Haynes, A.P.; Evans, P.A.; Johnson, R.J.; Rawstron, A.C.; McQuaker, P.; Smith, G.M.; Galvin, M.C.; Barnard, D.L.; Rusell, N.H.; Child, J.A.; Morgan, G.J. Detection of clonal rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD 34 positive selection. J. Clin. Pathol., 1996, 49, M112-M117.
13. García-Sanz, R.; López-Pérez, R.; Langerak, A.W.; González, D.; Chillón, M.C.; Balanzategui, A.; Mateos, M.V.; Alaejos, I.; González, M.; Van Dongen, J.J.; San Miguel, J.F. Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma. Haematologica, 1999, 84, 328-335.
14. González, M.; González, D.; López-Pérez, R.; García-Sanz, R.; Chillón, M.C.; Balanzategui, A.; Mateos, M.V.; Alaejos, I.; Langerak, A.W.; Orfão, A.; Van Dongen, J.J.; San Miguel, J.F. Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin's lymphoma. A comparison between different strategies. Haematologica, 1999, 84, 779-784.
15. Croce, C.M.; Shander, M.; Martinis, J.; Cicurel, L.; D'Ancona, G.G.; Dolby, T.W.; Koprowski, H. Chromosomal location of the genes for human immunoglobulin heavy chains. Proc. Natl. Acad. Sci. USA, 1979, 76, 3416-3419.
16. McBride, O.W.; Hieter, P.A.; Hollis, G.F.; Swan, D.; Otey, M.C.; Leder, P. Chromosomal location of human kappa and lambda inmunoglobulin IGH chain constant region genes. J. Exp. Med., 1982, 155, 1480-1490.
17. Bensmana, M.; Mattei, M.G.; Lefranc, M.-P. Localization of the human T-cell receptor gamma locus (TCRG) to 7p14-p15 by in situ hybridization. Cytogenet. Cell Genet., 1991, 56, 31-32.
18. Isobe, M.; Erikson, J.; Emanuel, B.S.; Nowell, P.C.; Croce, C.M. Location of gene for beta subunit of human T-cell receptor at band 7q35, a region prone to rearrangements in T cells. Science, 1985, 228, 580-582.
19. Tonegawa, S. Somatic generation of antibody diversity. Nature, 1983, 302, 575-581.
20. Davis, M.M.; Boniface, J.J.; Reich, Z.; Lyons, D.; Hampl, J.; Arden, B.; Chien, Y. Ligand recognition by alpha beta T cell receptors. Annu. Rev. Immunol., 1998, 16, 523-544.
21. Wang, L.D.; Clark, M.R. B-cell antigen-receptor signalling in lymphocyte development. Immunology, 2003, 110, 411-420.
22. Melchers, F. The pre-B-cell receptor: selector of fitting immunoglobulin heavy chains for the B- cell repertoire. Nat. Rev. Immunol., 2005, 5, 571-577.
23. Alt, F.W.; Yancopoulos, G.D.; Blackwell, T.K.; Wood, C.; Thomas, E.; Boss, M.; Coffman, R.; Rosenberg, N.; Tonegawa, S.; Baltimore, D. Ordered rearrangement of immunoglobulin heavy chain variable region segments. EMBO J., 1984, 3, 1209-1219.
24. Honjo, T.; Kinoshita, K.; Muramatsu, M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu. Rev. Immunol., 2002, 20, 165-196.
25. Klein, U.; Goossens, T.; Fischer, M.; Kanzler, H.; Braeuninger, A.; Rajewsky, K.; Küppers, R. Somatic hypermutation in normal and transformed human B cells. Immunol. Rev., 1998, 162, 261-280.
26. Peled, J.U.; Kuang, F.L.; Iglesias-Ussel, M.D.; Roa, S.; Kalis, S.L.; Goodman, M.F.; Scharff, M.D. The biochemistry of somatic hypermutation. Annu. Rev. Immunol. 2008, 26, 481-511.
27. González, D.; van der Burg, M.; García-Sanz, R.; Fenton, J.A.; Langerak, A.W.; González, M.; van Dongen, J.J.; San Miguel, J.F.; Morgan, G.J. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood, 2007, 110, 3112-3121.
28. Collins, M.K.; Tanigawa, G.; Kissonerghis, A.M.; Ritter, M.; Price, K.M.; Tonegawa, S.; Owen, M.J. Regulation of T-cell receptor gene expression in human T-cell development. Proc. Natl. Acad. Sci. USA, 1985, 82, 4503-4507.
29. Brack, C.; Hirama, M.; Lenhard-Schuller, R.; Tonegawa, S. A complete immunoglobulin gene is created by somatic recombination. Cell, 1978, 15, 1-14.
30. Tonegawa, S. That great time in Basel. Cell, 2004, 116 (2 Suppl), S99-101.
31. French, D.L.; Laskov, R.; Scharff, M.D. The role of somatic hypermutation in the generation of antibody diversity. Science, 1989, 244, 1152-1157.
32. Bagg, A.; Braziel, R.M.; Arber, D.A.; Bijwaard, K.E.; Chu, A.Y. Immunoglobulin heavy chain gene analysis in lymphomas: a multicenter study demonstrating the heterogeneity of performance of polymerase chain reaction assays. J. Mol. Diagn., 2002, 4, 81-9.
33. Derksen, P.W.; Langerak, A.W.; Kerkhof, E.; Wolvers-Tettero, I.L.; Boor, P.P.; Mulder, A.H.; Vrints, L.W.; Coebergh, J.W.; van Krieken, J.H.; Schuuring, E.; Kluin, P.M.; van Dongen, J.J. Comparison of different polymerase chain reaction-based approaches for clonality assessment of immunoglobulin heavy-chain gene rearrangements in B-cell neoplasia. Mod. Pathol., 1999, 12, 794-805.
34. Sandberg, Y.; van Gastel-Mol, E.J.; Verhaaf, B.; Lam, K.H.; van Dongen, J.J.; Langerak, A.W. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J. Mol. Diagn., 2005, 7, 495-503.
35. Linke, B.; Pyttlich, J.; Tiemann, M.; Suttorp, M.; Parwaresch, R.; Hiddemann, W.; Kneba, M. Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias. Leukemia, 1995, 9, 840-847.
36. Davis T.H.; Yockey C.E.; Balk S.P. Detection of clonal immunoglobulin gene rearrangements by polymerase chain reaction amplification and single-strand conformational polymorphism analysis. Am. J. Pathol., 1993, 142, 1841-1847.
37. Bourguin, A.; Tung, R.; Galili, N.; Sklar, J. Rapid, nonradioactive detection of clonal T-cell receptor gene rearrangements in lymphoid neoplasms. Proc. Natl. Acad. Sci. USA, 1990, 87, 8536-8540.
38. Kneba, M.; Bolz, I.; Linke, B.; Hiddemann, W. Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. Blood, 1995, 86, 3930-3937.
39. Linke, B.; Bolz, I.; Fayyazi, A.; von Hofen, M.; Pott, C.; Bertram, J.; Hiddemann, W.; Kneba, M. Automated high resolution PCR fragment analysis for identification of clonally rearranged immunoglobulin heavy chain genes. Leukemia, 1997, 11, 1055-1062.
40. Beaubier, N.T.; Hart, A.P.; Bartolo, C.; Willman, C.L.; Viswanatha, D.S. Comparison of capillary electrophoresis and polyacrylamide gel electrophoresis for the evaluation of T and B cell clonality by polymerase chain reaction. Diagn. Mol. Pathol., 2000, 9, 121-31.
41. Sykes, P.J.; Snell, L.E.; Brisco, M.J.; Neoh, S.H.; Hughes, E.; Dolman, G.; Peng, L.M.; Bennett, A.; Toogood, I.; Morley, A.A. The use of monoclonal gene rearrangement for detection of minimal residual disease in acute lymphoblastic leukemia of childhood. Leukemia, 1997, 11, 153-158.
42. Linke, B.; Pyttlich, J.; Tiemann, M.; Suttorp, M.; Parwaresch, R.; Hiddemann, W.; Kneba, M. Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias. Leukemia, 1995, 9, 840-47.
43. Potter, M.N.; Steward, C.G.; Maitland, N.J.; Oakhill, A. Detection of clonality in childhood B- lineage acute lymphoblastic leukaemia by the polymerase chain reaction. Leukemia, 1992, 6, 289-294.
44. de Boer, C.J.; van Krieken, J.H.; Schuuring, E.; Kluin, P.M. Bcl-1/ cyclin D1 in malignant lymphoma. Ann. Oncol., 1997, 8 (Suppl 2), 109-117.
45. Pott, C.; Schrader, C.; Gesk, S.; Harder, L.; Tiemann, M.; Raff, T.; Brüggemann, M.; Ritgen, M.; Gahn, B.; Unterhalt, M.; Dreyling, M.; Hiddemann, W.; Siebert, R.; Dreger, P.; Kneba, M. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood, 2006, 107, 2271-2278.
46. Yao, R.; Schneider, E. Detection of B- and T-cell-specific gene rearrangements in 13 cell lines and 50 clinical specimens using the BIOMED-2 and the original in vivo Scribe primers. Leuk. Lymphoma, 2007, 48, 837-840.
47. Evans, P.A.; Pott, C.H.; Groenen, P.J.; Salles, G.; Davi, F.; Berger, F.; Garcia, J.F.; van Krieken, J.H.; Pals, S.; Kluin, P.; Schuuring, E.; Spaargaren, M.; Boone, E.; Gonzalez, D.; Martinez, B.; Villuendas, R.; Gameiro, P.;, Diss, T.C.; Mills, K.; Morgan, G.J.; Carter, G.I.; Milner, B.J.; Pearson, D.; Hummel, M.; Jung, W.; Ott, M.; Canioni, D.; Beldjord, K.; Bastard, C.; Delfau- Larue, M.H.; van Dongen, J.J.; Molina, T.J.; Cabe&adas, J. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia, 2007, 21, 207-214.
48. Brüggemann, M.; White, H.; Gaulard, P.; Garcia-Sanz, R.; Gameiro, P.; Oeschger, S.; Jasani, B.; Ott, M.; Delsol, G.; Orfao, A.; Tiemann, M.; Herbst, H.; Langerak, A.W.; Spaargaren, M.; Moreau, E.; Groenen, P.J.; Sambade, C.; Foroni, L.; Carter, G.I.; Hummel, M.; Bastard, C.; Davi, F.; Delfau-Larue, M.H.; Kneba, M.; van Dongen, J.J.; Beldjord, K.; Molina, T.J. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia, 2007, 21, 215-21.
49. Liu, H.; Bench, A.J.; Bacon, C.M.; Payne, K.; Huang, Y.; Scott, M.A.; Erber, W.N.; Grant, J.W.; Du, M.Q. A practical strategy for the routine use of BIOMED-2 PCR assays for detection of B- and T-cell clonality in diagnostic haematopathology. Br. J. Haematol., 2007, 138, 31-43.
50. van Krieken, J.H.; Langerak, A.W.; Macintyre, E.A.; Kneba, M.; Hodges, E.; Sanz, R.G.; Morgan, G.J.; Parreira, A.; Molina, T.J.; Cabe&adas, J.; Gaulard, P.; Jasani, B.; Garcia, J.F.; Ott, M.; Hannsmann, M.L.; Berger, F.; Hummel, M.; Davi, F.; Brüggemann, M.; Lavender, F.L.; Schuuring, E.; Evans, P.A.; White, H.; Salles, G.; Groenen, P.J.; Gameiro, P.; Pott, Ch.; Dongen, J.J. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia, 2007, 21, 201-206.
51. Langerak, A.W.; Szczepa..ski, T.; van der Burg, M.; Wolvers-Tettero, I.L.; van Dongen, J.J. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia, 1997, 11, 2192-2199.
52. van der Harst, D.; de Jong, D.; Limpens, J.; Kluin, P.M.; Rozier, Y.; van Ommen, G.J.; Brand, A. Clonal B-cell populations in patients with idiopathic thrombocytopenic purpura. Blood, 1990, 76, 2321-2326.
53. Gonzalez, D.; Gonzalez, M.; Balanzategui, A.; Sarasquete, M.E.; Lopez-Perez, R.; Chillon, M.C.; Garcia-Sanz, R.; San Miguel, J.F. Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. Haematologica, 2005, 90, 906-913.
54. Catherwood, M.A.; Gonzalez, D.; Patton, C.; Dobbin, E.; Venkatraman, L.; Alexander, H.D. Improved clonality assessment in germinal centre/ post-germinal centre non-Hodgkin's lymphomas with high rates of somatic hypermutation. J. Clin. Pathol., 2007, 60, 524-528.
55. Campana, D.; Pui, C.H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood, 1995, 85, 1416-1434.
56. Pui, C.H.; Campana, D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia, 2000, 14, 783-785.
57. Campana, D. Status of minimal residual disease testing in childhood haematological malignancies. Br. J. Haematol., 2008, 143, 481-89.
58. Yamada, M.; Hudson, S.; Tournay, O.; Bittenbender, S.; Shane, S.S.; Lange, B.; Tsujimoto, Y.; Caton, A.J.; Rovera, G. Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc. Natl. Acad. Sci. USA, 1989, 86, 5123-5127.
59. Nizet, Y.; Van Daele, S.; Lewalle, P.; Vaerman, J.L.; Philippe, M.; Vermylen, C.; Cornu, G.; Ferrant, A.; Michaux, J.L.; Martiat, P. Longterm follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood, 1993, 82, 1618-1625.
60. Leal, E.; Jaloma-Cruz, A.R.; Barros-Núñez, P. High sensitivity of chemiluminescent methodology for detection of clonal CDR3 sequences in patients with acute lymphoblastic leukemia. Hematol. Oncol., 2004, 22, 55-61.
61. Owen, R.G.; Rawstron, A.C. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice. Br. J. Haematol., 2005, 128, 732-733.
62. Böttcher, S.; Ritgen, M.; Buske, S.; Gesk, S.; Klapper, W.; Hoster, E.; Hiddemann, W.; Unterhalt, M.; Dreyling, M.; Siebert, R.; Kneba, M.; Pott, C.; EU MCL MRD Group. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica, 2008, 93, 551-559.
63. Sarasquete, M.E.; García-Sanz, R.; González, D.; Martínez, J.; Mateo, G.; Martínez, P.; Ribera, J.M.; Hernández, J.M.; Lahuerta, J.J.; Orfão, A.; González, M.; San Miguel, J.F. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica, 2005, 90, 1365-1372.
64. Paiva, B.; Vidriales, M.B.; Cerveró, J.; Mateo, G.; Pérez, J.J.; Montalbán, M.A.; Sureda, A.; Montejano, L.; Gutiérrez, N.C.; García de Coca, A.; de Las Heras.; N, Mateos, M.V.; López-Berges, M.C.; García-Boyero, R.; Galende, J.; Hernández, J.; Palomera, L.; Carrera, D.; Martínez, R.; de la Rubia, J.; Martín, A.; Bladé, J.; Lahuerta, J.J.; Orfao, A.; San Miguel, J.F.; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, 2008, 112, 4017-4023.
65. Vidriales, M.B.; San-Miguel, J.F.; Orfao, A.; Coustan-Smith, E.; Campana, D. Minimal residual disease monitoring by flow cytometry. Best. Pract. Res. Clin. Haematol., 2003, 16, 599-612.
66. Rawstron, A.C.; Villamor, N.; Ritgen, M.; Bottcher, S.; Ghia, P.; Zehnder, J.L.; Lozanski, G.; Colomer, D.; Moreno, C.; Geuna, M.; Evans, P.A.; Natkunam, Y.; Coutre, S.E.; Avery, E.D.; Rassenti, L.Z.; Kipps, T.J.; Caligaris-Cappio, F.; Kneba, M.; Byrd, J.C.; Hallek, M.J.; Montserrat, E.; Hillmen, P. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia, 2007, 21, 956-964.
67. Lefranc, M.-P. http://imgt.cines.fr [Accessed 1989].
68. Althaus,H.H.;Muller,W. http://vbase.mrc-cpe.cam.ac.uk [Accessed 1997].
69. Verhagen, O.J.; Willemse, M.J.; Breunis, W.B.; Wijkhuijs, A.J.; Jacobs, D.C.; Joosten, S.A.; van Wering, E.R.; van Dongen, J.J.; van der Schoot, C.E. Application of germline IGH probes in realtime quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia, 2000, 14, 1426-1435.
70. van Dongen, J.J.; Macintyre, E.A.; Gabert, J.A.; Delabesse, E.; Rossi, V.; Saglio, G.; Gottardi, E.; Rambaldi, A.; Dotti, G.; Griesinger, F.; Parreira, A.; Gameiro, P.; Diáz, M.G.; Malec, M.; Langerak, A.W.; San Miguel, J.F.; Biondi, A. Standardized RTPCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease. Leukemia, 1999, 13, 1901-1928.
71. Gabert, J.; Beillard, E.; van der Velden, V.H.; Bi, W.; Grimwade, D.; Pallisgaard, N.; Barbany, G.; Cazzaniga, G.; Cayuela, J.M.; Cavé, H.; Pane, F.; Aerts, J.L.; De Micheli, D.; Thirion, X.; Pradel, V.; González, M.; Viehmann, S.; Malec, M.; Saglio, G.; van Dongen, J.J. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 2003, 17, 2318-2357.
72. Steenbergen, E.J.; Verhagen, O.J.; van den Berg, H.; van Leeuwen, E.F.; Behrendt, H.; Slater, R.R.; von dem Borne, A.E.; van der Schoot, C.E. Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B precursor acute lymphoblastic leukemia. Leukemia, 1997, 11, 1258-1265.
73. Rimelen, V.; Ferrand, C.; Debecker, A.; Sovalat, H.; Tancredi, C.; Eidenschenk, A.; Hénon, P. Relative quantification of residual tumor cells by lightcycler real-time IgH PCR in autografted multiple myeloma patients. Leukemia, 2005, 19, 492-495.
74. Ririe, K.M.; Rasmussen, R.P.; Wittwer, C.T. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal. Biochem., 1997, 245, 154-160.
75. Nakao, M.; Janssen, J.W.; Flohr, T.; Bartram, C.R. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res., 2000, 60, 3281-3289.
76. Eckert, C.; Scrideli, C.A.; Taube, T.; Songia, S.; Wellmann, S.; Manenti, M.; Seeger, K.; Biondi, A.; Cazzaniga, G. Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes. Leukemia, 2003, 17, 2517-2524.
77. van der Velden, V.H.; Cazzaniga, G.; Schrauder, A.; Hancock, J.; Bader, P.; Panzer-Grumayer, E.R.; Flohr, T.; Sutton, R.; Cave, H.; Madsen, H.O.; Cayuela, J.M.; Trka, J.; Eckert, C.; Foroni, L.; Zur-Stadt, U.; Beldjord, K.; Raff, T.; van der Schoot, C.E.; van Dongen, J.J. European StudyGroup on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia, 2007, 21, 604-611.
78. Coustan-Smith, E.; Sancho, J.; Hancock, M.L.; Boyett, J.M.; Behm, F.G.; Raimondi, S.C.; Sandlund, J.T.; Rivera, G.K.; Rubnitz, J.E.; Ribeiro, R.C.; Pui, C.H.; Campana, D. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 2691-2696.
79. Zhou, J.; Goldwasser, M.A.; Li, A.; Dahlberg, S.E.; Neuberg, D.; Wang, H.; Dalton, V.; McBride, K.D.; Sallan, S.E.; Silverman, L.B.; Gribben, J.G. Dana-Farber Cancer Institute ALL Consortium. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood, 2007, 110, 1607-1611.
80. Flohr, T.; Schrauder, A.; Cazzaniga, G.; Panzer-Grumayer, R.; van der Velden, V.; Fischer, S.; Stanulla, M.; Basso, G.; Niggli, F.K.; Schäfer, B.W.; Sutton, R.; Koehler, R.; Zimmermann, M.; Valsecchi M.G.; Gadner, H.; Masera, G.; Schrappe, M.; van Dongen, J.J.; Biondi, A.; Bartram, C.R. International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia, 2008, 22, 771-782.
81. van Dongen, J.J.; Seriu, T.; Panzer-Grümayer, E.R.; Biondi, A.; Pongers-Willemse, M.J.; Corral, L.; Stolz, F.; Schrappe, M.; Masera, G.; Kamps, W.A.; Gadner, H.; van Wering, E.R.; Ludwig, W.D.; Basso, G.; de Bruijn, M.A.; Cazzaniga, G.; Hettinger, K.; van der Does-van den Berg, A.; Hop, W.C.; Riehm, H.; Bartram, C.R. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 1998, 352, 1731-1738.
82. Cavé, H.; van der Werff ten Bosch, J.; Suciu, S.; Guidal, C.; Waterkeyn, C.; Otten, J.; Bakkus, M.; Thielemans, K.; Grandchamp, B.; Vilmer, E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N. Engl. J. Med., 1998, 339, 591-598.
83. Bakkus, M.H.; Bouko, Y.; Samson, D.; Apperley, J.F.; Thielemans, K.; Van Camp, B.; Benner, A.; Goldschmidt, H.; Moos, M.; Cremer, F.W. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br. J. Haematol., 2004, 126, 665-674.
84. Pfitzner, T.; Reiser, M.; Barth, S.; Borchmann, P.; Schulz, H.; Schinköthe, T.; Oberhäuser, F.; Wessels, J.; Tur, M.; Diehl, V.; Engert, A. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann. Hematol., 2002, 81, 258-66.
85. Ladetto, M.; Corradini, P.; Vallet, S.; Benedetti, F.; Vitolo, U.; Martelli, M.; Brugiatelli, M.; Coser, P.; Perrotti, A.; Majolino I.; Fioritoni, G.; Morandi, S.; Musso, M.; Zambello, R.; Chisesi, T.; Di Renzo, N.; Vivaldi, P.; De Crescenzo, A.; Gallamini, A.; Salvi, F.; Santini, G.; Boccomini, C.; Sorio, M.; Astolfi, M.; Drandi, D.; Pileri, A.; Tarella, C. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood, 2002, 100, 1559-1565.
86. Paganin, M.; Zecca, M.; Fabbri, G.; Polato, K.; Biondi, A.; Rizzari, C.; Locatelli, F.; Basso, G. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia, 2008, 22, 2193-2200.
87. Bader, P.; Kreyenberg, H.; Henze, G.H.; Eckert, C.; Reising, M.; Willasch, A.; Barth, A.; Borkhardt, A.; Peters, C.; Handgretinger, R.; Sykora, K.W.; Holter, W.; Kabisch, H.; Klingebiel, T.; von Stackelberg, A.; The ALL-REZ BFM Study Group. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia. J. Clin. Oncol., 2008, 27, 377-384.
88. van der Velden, V.H.; Joosten, S.A.; Willemse, M.J.; van Wering, E.R.; Lankester, A.W.; van Dongen, J.J.; Hoogerbrugge, P.M. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia, 2001, 15, 1485-1487.
89. Uzunel, M.; Mattsson, J.; Jaksch, M.; Remberger, M.; Ringdén, O. The significance of graft- versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood, 2001, 98, 1982-1984.
90. Krejci, O.; van der Velden, V.H.; Bader, P.; Kreyenberg, H.; Goulden, N.; Hancock, J.; Schilham, M.W.; Lankester, A.; Révész, T.; Klingebiel, T.; van Dongen, J.J. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant., 2003, 32, 849-851.